DiaMedica Therapeutics, Inc. (DMAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DMAC's 50-day simple moving average ...
DiaMedica Therapeutics, Inc. (DMAC) has been on a downward spiral lately with significant selling pressure. After declining 19.8% over the past four weeks, the stock looks well positioned for a trend ...
Getting your Trinity Audio player ready... Derek Wolfe wasn’t retired for long. After signing a one-day contract in July to retire with the Broncos, the team that had drafted him in 2012, the former ...
Denver sports radio veteran Darren McKee, widely recognized as DMac, is set to join KSE Radio Ventures’ Altitude Sports Radio 92.5 (KKSE). DMac will join the new midday show P.H.D., alongside Scott ...
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DiaMedica Therapeutics, Inc. (DMAC) is a stock that can certainly ...
The average one-year price target for DiaMedica Therapeutics (NasdaqCM:DMAC) has been revised to $15.81 / share. This is an increase of 25.68% from the prior estimate of $12.58 dated November 14, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results